Benign Multiple Sclerosis (MS)

Benign multiple sclerosis (MS) is a mild course of MS seen in 5-10% of MS patients. In people affected by benign MS, there is no worsening of functional ability even after 15 years of diagnosis. Currently, there is no way of predicting this form of MS at the time of diagnosis.

Studies have demonstrated that a benign course of MS is characterized by the absence of relapses and stable disability after 20-30 years of diagnosis. Benign MS patients usually have very few relapses followed by full recovery, and the effects of the condition are more sensory than mobility related.

Benign MS and disease progression

In an attempt to define benign MS, studies will often measure disease progression. Some skeptics feel that the term “benign” isn’t appropriate as the disease eventually progresses and becomes worse.

Neurologists widely use the expanded disability status scale (EDSS) to recognize benign MS. The EDSS measures the level of physical disability in a patient. A low EDSS score (3 or less) may be indicative of benign MS. Such a score would mean that the patient can walk around—though mild disability is present—over 10 years following diagnosis.

The impact of EDSS scores on therapy choices is high. To avoid the possibility of drug side effects, neurologists often defer treatment in people affected with benign MS until they start expressing severe symptoms.

Symptoms of benign MS

While physical disability is a symptom of benign MS, there are lesser-known symptoms of the disease. These symptoms include:

  • Depression
  • Fatigue
  • Cognitive issues
    • Loss of short-term memory
    • Concentration impairment

Research on benign MS

A study published in the Journal of Neurology, Neurosurgery & Psychiatry aimed to establish the characteristics of benign MS and assess key prognostic factors. The study was carried out in parts of Northern Ireland and included 259 MS patients, of which 181 had MS for over 10 years and 36 had benign MS more than 10 years after onset.

On comparison of clinical and demographic data of the patient groups, the study identified 33 patients with benign MS. The results of the study showed that younger women are more susceptible to benign MS and 33.3% of them experienced sensory and optic neuritis as the most common symptoms.

In the case of people with late onset, progressive forms of MS were more likely than a benign course and these patients presented with motor disturbance. A follow-up study confirmed that benign MS patients had a mild course than non-benign forms, though it was concluded that the label “benign MS” is mostly temporary as progression of disability was significant.

Role of genes in benign MS

According to a new study, people with benign MS have a unique pattern of gene activity represented by the slowing of a key protein synthesis pathway that eventually leads to cell apoptosis.

The team of researchers from Sheba Medical Center in Israel compared the gene expression profile of benign MS and relapsing-remitting MS (RRMS) patients. Blood cells from 36 RRMS patients and 31 benign MS patients (after 17 years of diagnosis and <3 EDSS score) were collected.

On comparison of the two groups using microarrays, 406 genes were found to be different and over 50% of these genes were less active in the case of patients with benign MS. The researchers found that less active genes were linked to the RNA polymerase I (Pol I) pathway, which synthesizes several components of the ribosome.

Researchers also found that benign MS patients had an overactive p53 pathway, which promotes cell death, causing the suicide of self-reactive immune cells. According to the team, this may explain why symptoms are less severe in benign MS.

References

Further Reading

Last Updated: Feb 27, 2019

Susha Cheriyedath

Written by

Susha Cheriyedath

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2019, February 27). Benign Multiple Sclerosis (MS). News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/health/Benign-Multiple-Sclerosis-(MS).aspx.

  • MLA

    Cheriyedath, Susha. "Benign Multiple Sclerosis (MS)". News-Medical. 31 October 2024. <https://www.news-medical.net/health/Benign-Multiple-Sclerosis-(MS).aspx>.

  • Chicago

    Cheriyedath, Susha. "Benign Multiple Sclerosis (MS)". News-Medical. https://www.news-medical.net/health/Benign-Multiple-Sclerosis-(MS).aspx. (accessed October 31, 2024).

  • Harvard

    Cheriyedath, Susha. 2019. Benign Multiple Sclerosis (MS). News-Medical, viewed 31 October 2024, https://www.news-medical.net/health/Benign-Multiple-Sclerosis-(MS).aspx.

Comments

  1. Renauld Clare Renauld Clare Netherlands says:

    After bouts with many neurologists I was diagnosed of MULTIPLE SCLEROSIS, I was placed on medications which helped but my health was fast declining. Finally, I was introduced to Herbal HealthPoint and their effective Multiple Sclerosis protocol. This protocol relieved symptoms significantly, even better than the medications I was given. Visit ww w. healthherbalpoint. c om. First month on treatment, my tremors mysterious stopped, had improvement walking. After I completed the treatment, all symptoms were gone. I live a more productive life.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans